Sareum Holdings (FRA:RYH0) Valuation Rank


FRA:RYH0 Sareum Holdings PLC FRA:RYH0
37 GF Score
Price €0.20
! 3 Warning Signs
View Full Analysis

What is Sareum Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sareum Holdings Valuation Rank Related Terms

FRA:RYH0
37GF Score
Sareum Holdings PLC FRA:RYH0
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sareum Holdings Business Description

Other Exchanges SAR:UK
Address Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
37GF Score

Get the complete analysis for FRA:RYH0

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price